Vitiligo is a non contagious acquired pigmentation disorder characterized by sharply defined white patches of variable shape and dimensions, increasing in size and number with time. The present study assessed anti-melanocyte antibodies (AMAs) in patients of vitiligo.
Materials & Methods: The present study was conducted on 72 cases of vitiligo of both genders. The severity of vitiligo was assessed according to the Vitiligo Area Scoring Index (VASI). AMA was measured by human melanocyte antibody enzyme-linked immunosorbent assay (ELISA) Kit.
Results: In group I (cases), there were 40 males and 32 females and in group II (control), there were 34 males and 38 females. The mean VASI score in males was 8.13 and in females was 8.45, duration of disease was 6.24 years in males and 6.17 years in females. The difference was significant (P<0.05). The mean AMA in group I was 14.7 mg/ml and in group II was 5.2 mg/ml. The difference was significant (P<0.05).
Conclusion: Authors found that there was significantly higher level of antimelanocyte antibodies (AMA) in patients than control.